Tratamiento oportuno del paciente psicótico

Referencias

1. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-97.

2. Suokas JT, Perälä J, Suominen K, Saarni S, Lönnqvist J, Suvisaari JM. Epidemiology of suicide attempts among persons with psychotic disorder in the general population. Schizophr Res 2010;124:22-8.

3. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with firstepisode psychosis. Acta Psychiatr Scand 2005;112:141-8.

4. Folsom DP, Hawthorne W, Lindamer L, et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. Am J Psychiatry 2005; 162:370-6.

5. Brekke JS, Prindle C, Bae SW, Long JD. Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv 2001;52:1358-66.

6. Douglas KS, Guy LS, Hart SD. Psychosis as a risk factor for violence to others: a meta-analysis. Psychol Bull 2009;135: 679-706.

7. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012;37:4-15.

8. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III — the final common pathway. Schizophr Bull 2009;35:549-62.

9. Lodge DJ, Grace AA. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci 2011;32: 507-13.

10. Nakazawa K, Zsiros V, Jiang Z, et al. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012;62:1574-83.

11. Lander SS, Khan U, Lewandowski N, et al. Glutamate Dehydrogenase-Deficient Mice Display Schizophrenia-Like Behavioral Abnormalities and CA1-Specific Hippocampal Dysfunction. Schizophr Bull 2018 February 20 (Epub ahead of print).

12. van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 2015;29:254-63.

13. Sánchez-Blázquez P, Rodríguez-Muñoz M, Garzón J. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol 2014;4:169.

14. González-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007;53:439-52.

15. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis — preliminary observations. Biol Psychiatry 1970;2:95-107.

16. Sullivan PF, Daly MJ, O’Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 2012;13:537-51.

17. Pers TH, Timshel P, Ripke S, et al. Comprehensive analysis of schizophreniaassociated loci highlights ion channel pathways and biologically plausible candidate causal genes. Hum Mol Genet 2016; 25:1247-54.

18. Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature 2016;530:177-83.

19. Adelson JD, Sapp RW, Brott BK, et al. Developmental sculpting of intracortical circuits by MHC class I H2-Db and H2-Kb. Cereb Cortex 2016;26:1453-63.

20. Fourgeaud L, Davenport CM, Tyler CM, Cheng TT, Spencer MB, Boulanger LM. MHC class I modulates NMDA receptor function and AMPA receptor trafficking. Proc Natl Acad Sci U S A 2010;107: 22278-83.

21. Murphy KC, Owen MJ. Velo-cardiofacial syndrome: a model for understanding the genetics and pathogenesis of schizophrenia. Br J Psychiatry 2001;179:397-402.

22. Kirov G. CNVs in neuropsychiatric disorders. Hum Mol Genet 2015;24:R45-R49.

23. Faust TW, Chang EH, Kowal C, et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A 2010;107: 18569-74.